Effects of HIV protease inhibitor therapy on lipid metabolism.
about
Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase InhibitorsThe roles of genetic polymorphisms and human immunodeficiency virus infection in lipid metabolismNelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activityAggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus.Plasma bile acid concentrations in patients with human immunodeficiency virus infection receiving protease inhibitor therapy: possible implications for hepatotoxicityDevelopment of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunctionEffects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trialInsulin resistance and adipokines serum levels in a caucasian cohort of hiv-positive patients undergoing antiretroviral therapy: a cross sectional study.Molecular bases of progeroid syndromes.HIV protease inhibitors in gut barrier dysfunction and liver injury.Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir)Mixed modeling and multiple imputation for unobservable genotype clustersSex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population.Temporal trends in the discontinuation of first-line antiretroviral therapyMetabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent.Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk.The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfectionsThe Relationship Between HIV Infection and Cardiovascular Disease.Investigational protease inhibitors as antiretroviral therapies.Human paraoxonase-1 activity is related to the number of CD4+ T-cells and is restored by antiretroviral therapy in HIV-1-infected individuals.Drug-Induced Liver Injury in HIV Patients.Insulin-like growth factor-I-forkhead box O transcription factor 3a counteracts high glucose/tumor necrosis factor-α-mediated neuronal damage: implications for human immunodeficiency virus encephalitis.Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.Alterations in lipid transfer to high-density lipoprotein (HDL) and activity of paraoxonase-1 in HIV+ patients.The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C
P2860
Q25255216-CDFA96FE-5AD5-48EE-9475-E8C3BEBE85D4Q26764925-C662A9BA-6A28-4B43-96C6-6636B54D6746Q27021950-3648538D-058A-4014-8BD1-513284BB950FQ28083142-FB086316-5ED9-447A-9886-0C48F8A0EC3EQ30576375-DDAE3E2B-604D-48CB-8427-455F6F941967Q33799279-6B74600D-300C-44BE-974E-C61FBEF75AFEQ33901061-95500986-40CA-4FC0-80F2-C176490B3D56Q34217293-39F378D1-AF08-43B9-88FF-347D482A5E24Q34564051-3D2FCD4B-BA4A-446D-84A1-491B80081FD7Q34567458-204D6716-D84E-45C7-B4B3-8F301DC7CBA9Q34617496-E39C8D20-EE45-4978-8C55-21E2412C8699Q35009815-65CEF221-6030-45C3-A237-1D44B1A094A4Q35025730-0C448B11-4DE0-40E7-9D21-DCC2FCAF69DAQ35093189-4FCC2057-28E1-45F9-9416-BECCCC1ED3B9Q35567828-0E52792F-A0A1-47DE-B6C0-F0489E674622Q36011828-12CF14D7-A247-40F2-ACDA-A2A9ECDEB564Q36070094-4467142E-BADB-4FDA-A65E-633D68A06235Q36093602-962DA439-C47A-45CA-B152-83C700CA41E8Q36250357-BEDB1549-FEF0-4E0F-AF1D-A27531AB7C68Q36441470-7E7E6EE7-4C90-4188-AD5D-D73DDFA8DF32Q36528535-8AD68686-C9A5-429B-8758-6A685421141DQ36773367-1D149BFF-1B20-47F2-A94C-CF710422CBF3Q37332151-66DEBC50-5FB7-4CBC-A6E4-E71A11CF496BQ37429096-AA3D34E8-C653-40AD-92E4-54346A0D7E73Q37582521-08EFFF23-78EC-45D8-B8F1-0686E7536287Q37639821-A70ED2C9-D5A7-47B3-8B3B-13A065E8A21FQ37699731-DE628DC3-BAED-4785-A13E-0B7DF8F9D6DEQ41821482-9D6FD0C8-4B4E-4471-B775-620E1954EA01Q45014717-76715A92-7301-4E84-B105-AE3D1F373903Q46350063-8DA9769C-C42F-4B4B-9A7A-BC52B909F7A5Q54215275-DF6F1BD1-4DD9-4867-9496-648BE308F3F9Q56746595-BC6CB4C5-E3B8-496A-A228-FF1EE5C430C6
P2860
Effects of HIV protease inhibitor therapy on lipid metabolism.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Effects of HIV protease inhibitor therapy on lipid metabolism.
@ast
Effects of HIV protease inhibitor therapy on lipid metabolism.
@en
type
label
Effects of HIV protease inhibitor therapy on lipid metabolism.
@ast
Effects of HIV protease inhibitor therapy on lipid metabolism.
@en
prefLabel
Effects of HIV protease inhibitor therapy on lipid metabolism.
@ast
Effects of HIV protease inhibitor therapy on lipid metabolism.
@en
P1476
Effects of HIV protease inhibitor therapy on lipid metabolism.
@en
P2093
David Y Hui
P356
10.1016/S0163-7827(02)00046-2
P577
2003-03-01T00:00:00Z